Doug Drysdale @insidepharma

Every migraine drug that actually works, works through serotonin. We’ve just kept hitting that system one receptor at a time. Triptans got there first - 5-HT1B/1D agonists. Effective, but the 1B arm constricts blood vessels, which is exactly why they’re off-limits for so many patients carrying cardiovascular risk. Ditans came next. Lasmiditan proved you could hit 5-HT1F on its own, skip the vasoconstriction entirely, and still shut down trigeminal pain signaling. Then the tryptamine data showed up. Controlled trials of psilocybin - a 5-HT2A agonist - cut migraine and cluster attack frequency for weeks after a single dose. A different, longer-lasting kind of relief than anything the acute drugs deliver. And underneath all of it sits the oldest class of all: the ergolines. Methysergide was the first true migraine preventive, back in 1959. Dihydroergotamine is still in use today. Their secret was never a single receptor - ergolines are broad serotonergic agonists that reach 1B, 1D, 1F and 2A at the same time. That’s the insight behind BETR-001. BETR-001 is a single, patented stereoisomer of 2-bromo-LSD - an ergoline. So its pharmacology doesn’t have to pick one door. It’s positioned to engage the same 5-HT1B/1D targets triptans hit, the 5-HT1F target ditans hit, and the 5-HT2A target the tryptamines hit - as one oral, non-hallucinogenic molecule, without the vascular liability and without the trip. No one has tried to treat migraine by unifying all three validated axes in a single compound. But every one of those axes has already been de-risked by a drug that reached patients. The combination is what’s new. The mechanisms aren’t. We’re finishing IND-enabling work now, with human trials ahead. Chronic cluster headache and migraine, which affects 40 million people in the US alone and is the 3rd most prevalent disease globally. You don’t always need a new target. Sometimes you need one molecule that finally hits all the right ones at once. #Migraine #Neuroscience #DrugDevelopment #ClusterHeadache #CNS #Serotonin

The future of Alzheimer's isn't just treatment - it's prevention before the first symptom appears. Today, Abu Dhabi announced a groundbreaking genomics-driven clinical trial that could rewrite our approach to neurodegeneration. Using data from the Emirati Genome Programme covering nearly one million people, researchers are identifying high-risk individuals - particularly those with variants like APOE4 - and enrolling them in a preventive study of Halia Therapeutics, Inc.'s HT-4253. This LRRK2 inhibitor aims to stop nerve cell inflammation and amyloid buildup at its source, a fresh approach beyond current amyloid-targeting therapies. Led by M42 Health’s Insights Research Organization and Solutions in partnership with local health authorities, this trial embodies precision, proactive medicine. In a world where dementia cases are projected to surge, initiatives like this signal real hope for extending healthy brain years and transforming longevity outcomes. What an inspiring step forward for neuroscience and global health. #Alzheimers #Neuroscience #PrecisionMedicine #Longevity #Biopharma

@DanielSnow37987 Not a “no” yet but I agree surprising for this one.

FDA staff recommends against adding any of these 7 peptides to the 503A Bulks List: • BPC-157 (free base/acetate) • KPV (free base/acetate) • TB-500 (free base/acetate) • MOTS-c (free base/acetate) • Emideltide/DSIP (free base/acetate) • Epitalon (free base/acetate) • Semax (free base/acetate) What it means: The 503A Bulks List allows compounding pharmacies to create customized versions for patients with a prescription. Without it, these peptides likely won’t be legally compoundable under 503A if the recommendation holds - sharply restricting regulated access. Market impact: This could keep the gray/research-only market strong. Expect continued demand via research chemical sites, possible price spikes from limited regulated supply, shifts to international sources, and patients continuing to turn to non-pharmacy channels. The July 23-24 PCAC meeting will advise, but FDA makes the final call later. Big implications for access, pricing, and the peptide ecosystem.

The FDA just cleared an AI-designed molecule into Phase 2 for Parkinson's. The part worth your attention isn't the speed. It's the kind of target it cracked. On June 29, Gain Therapeutics got FDA clearance to advance GT-02287 into Phase 2 in Parkinson's, with or without a GBA1 mutation. It's an oral, brain-penetrant allosteric modulator that restores glucocerebrosidase (GCase), the lysosomal enzyme that misfolds and stops working in GBA1-linked Parkinson's. In the Phase 1b extension, all 16 participants were still on study at five months, and CSF glucosylsphingosine, a substrate that piles up when GCase fails, fell an average 81% at 90 days in patients with elevated baseline levels. It is the first allosteric modulator out of Gain's Magellan AI platform to reach the clinic. Here is what I would underline for anyone pricing AI drug discovery. Most of the capital so far has chased AI that generates new molecules against targets we already knew how to drug. That is the cheap, crowded end of the problem, and it is where the biobucks deals keep getting signed. The harder, more defensible edge is drugging what human medicinal chemistry couldn't. An allosteric pocket that quietly re-folds a broken enzyme is exactly that kind of target. You don't reach it by screening a library, you get there by modeling how a protein folds and moves. A platform that can do that repeatably owns something rare: access to targets nobody else can drug. Speed against known pockets gets copied. One caveat I won't skip. An 81% drop in a substrate biomarker is target engagement, not disease modification. Parkinson's is one of the most efficient ways to lose money in this business, full of drugs that moved a marker and went nowhere in the clinic. "AI-designed" tells you where the molecule came from, not whether it works. Phase 2, starting in the third quarter, is where that question actually gets answered. So if you're underwriting an AI-discovery platform this morning: are you paying for speed against targets everyone can already hit, or for the ability to drug the ones that were off the table? Only one of those is hard to copy. #Parkinsons #AIDrugDiscovery #Biotech #DrugDevelopment #Neuroscience

Almost everyone in the psychedelic and neuroplastogen field is running at the same two doors: depression and anxiety. Look at the 2026 landscape and the convergence is striking. Of the roughly 30 5-HT2A agonist candidates in active development, about three-quarters are aimed at major depression, treatment-resistant depression, or generalized anxiety. Three separate Phase 3 programs are reading out in those indications this year alone. It's the most validated commercial path. It's also the most crowded one - and crowding is a strategy risk. When a dozen assets chase the same endpoints in the same patients, differentiation gets hard and pricing gets harder. That's exactly why BETR-001 stands out to me. BETR-001 is a single, patented stereoisomer of 2-bromo-LSD - and its receptor pharmacology is genuinely differentiated. It's a non-hallucinogenic 5-HT2A partial agonist that drives neuroplasticity without the head-twitch / psychedelic signature, and without the 5-HT2B activity associated with cardiac valvulopathy. It's oral, doesn't induce tolerance on repeat dosing, and is positioned to sit outside the controlled-substance and clinic-monitoring burden that constrains classic psychedelics. That profile points somewhere the crowd isn't: headache. 2-bromo-LSD has real clinical evidence in cluster headache - the "suicide headache" - one of the most severe, most underserved conditions in neurology. A differentiated mechanism, an orphan regulatory path, and a place to lead rather than follow. And the same serotonergic biology that makes BETR-001 compelling in cluster headache extends naturally to migraine - a far larger population where a non-hallucinogenic, at-home oral could reach patients the current crop of clinic-bound psychedelics never will. After a few drug-development cycles, the lesson keeps repeating: you don't win by being the thirteenth asset through the most crowded door. You win where the biology gives you a reason to be different. BETR-001 has that reason. #Neuroscience #DrugDevelopment #Psychedelics #ClusterHeadache #Migraine #CNS #Neuroplasticity

x.com/i/article/2071…

A major breakthrough in healthy aging could reshape how we understand brain health and longevity. Researchers at Northeastern University, working with Harvard, published a landmark Nature Aging study that mapped aging-related genes into interconnected “neighborhoods” within the human protein interaction network. By linking these modules to the 11 hallmarks of aging, the team screened thousands of approved drugs and identified promising candidates that may support longevity or slow processes tied to neurodegeneration and metabolic decline. One notable finding involved the active ingredient in common nasal sprays such as Afrin, which showed potential to improve cell-to-cell communication - an important hallmark of aging. This network-based approach is more than theoretical: it was validated against drugs already being tested in longevity trials and offers a smarter path for repurposing well-understood, approved compounds. For biopharma, neurology, and longevity researchers, it could speed discovery in a field where new drug development has traditionally been slow and costly. The possibility of turning everyday medicines into tools for healthier aging - and for protecting against diseases such as Alzheimer’s or Parkinson’s - highlights the promise of this systems-level approach. It connects metabolic health, neuroscience, and preventive medicine in a practical new way.

x.com/i/article/2070…

@milesdeutscher You’re stacking twelve superlatives and hoping taste falls out. It usually doesn’t. It produces a different flavor of generic, because “be premium and opinionated” is itself one of the most common things in the training data.

I personally believe that the classical psychedelic experiences contribute to efficacy in psychiatric disorders. But there is no rationale why a trip would be needed for a CNS or Pain disorder. Also, there are several historical precedents for ergolines in migraine and cluster headache.

What if you could get the therapeutic upside of LSD without the trip? That question sits at the center of a molecule called 2-bromo-LSD - a non-hallucinogenic neuroplastogen. 2-bromo-LSD is what it sounds like. The LSD molecule, with a single bromine atom added at one position on the ring. Same family. Same serotonergic scaffold. One small change. Albert Hofmann first made it in the 1950s. It was coded BOL-148. In human studies it did something surprising: no hallucinations. It even blocked the hallucinogenic effect of LSD itself, dose for dose. For decades the field wrote it off. No trip was read as no activity. That read was wrong. LSD's psychedelic effects are tied to how it activates the 5-HT2A serotonin receptor. The bromine changes how the molecule engages that receptor. You lose the hallucinations. You keep the serotonergic and neuroplastic activity that may carry the therapeutic benefit. The brain still rewires - its neuroplastic effects are profound. Why does that matter for drug development? - No hallucinations means no clinician sitting with a patient for eight to twelve hours per dose. That one fact changes the economics and the access. - It opens the door to an oral pill taken at home. - It supports repeat and chronic dosing. Classic psychedelics fight tolerance and chronic conditions need chronic dosing. - Made through a route that does not start from LSD, it is not a scheduled controlled substance. That removes a large regulatory and supply burden. The human signal that put this on the map: a small 2010 study (Karst et al.) reported benefit in cluster headache, one of the most painful conditions in medicine and one with few good options. And migraine runs on the same wiring: triptans, ditans and ergolines all work through serotonin receptors this molecule already engages, so the cluster-headache rationale extends straight to migraine. One more distinction worth making. The version tested decades ago, BOL-148, was the racemic mixture: the active molecule plus its inactive mirror images in the same vial. BETR-001 is the single active stereoisomer, the (6R,9R) form, isolated and patented. Same atoms, one clean form, and composition-of-matter IP the old racemate never had. The premise is simple and worth understanding: separate the healing from the hallucination, and you change what a serotonergic medicine can be. @BetterLifeBio $BETRF #Neuroscience #CNS #Psychedelics

@psybalazs @definiumtx However, in most AD trials the treatment is daily, providing continued daily reinforcement of the placebo effect. Not realistic to expect the same effect from a single dose.

@BrianRoemmele @grok What hardware are you running this on, Brian?

Link to PR: newsfilecorp.com/release/302788…

Big Momentum for @BetterLifeBio ($BETR) BetterLife just took a major step forward in advancing its groundbreaking candidate BETR-001 (2-bromo-LSD) toward the clinic. The company has engaged Syner-G BioPharma Group to oversee GMP manufacturing for its IND submission and upcoming Phase 1 program. This partnership brings top-tier CMC and regulatory expertise to ensure high-quality, scalable production of BETR-001 - a non-hallucinogenic LSD derivative designed to deliver powerful therapeutic benefits without the hallucinations or cardiac risks associated with traditional LSD. Key highlights: Targets significant unmet needs in chronic cluster headaches and chronic migraines Acts as a potent neuroplastogen while engaging key 5-HT receptors IND-enabling studies wrapping up, with IND filing and Phase 1 start targeted for Q1 2027 Quote from CEO Dr. Ahmad Doroudian: "We are pleased to be partnering with Syner-G to oversee the proprietary manufacturing of BETR-001. Their CMC and regulatory expertise strengthen our path to an IND filing and the start of Phase 1 in the first quarter of 2027." This is excellent execution and de-risking as BetterLife moves confidently from preclinical into human trials. Non-hallucinogenic neuroplastogens like BETR-001 represent the next wave in neuropsychiatric and neurological treatments, and BetterLife is well-positioned to lead. Huge congratulations to the team! Looking forward to more clinical progress ahead. #BETR #BETR001 #Psychedelics #Biotech #Neurology #MentalHealth #ClusterHeadache #Migraine

Migraine affects roughly 39 million Americans and more than a billion people worldwide, and ranks among the leading causes of disability in adults under 50. Most are still treated for the attack, not the disease. The throughline is consistent. Serotonin has driven migraine therapy for six decades, and chronic safety has been the recurring constraint. Methysergide, derived from lysergic acid, was introduced in 1959 as the first effective migraine preventive. The efficacy was real. Within a few years, chronic use was linked to retroperitoneal and cardiac fibrosis, and the drug was pushed to last-line use. An early and hard lesson. Triptans followed in the 1990s. Acting on 5-HT1B/1D receptors, they set the acute standard, but they are attack-only and carry cardiovascular contraindications. The CGRP class arrived between 2018 and 2020, the first migraine-specific preventives in a generation, now anchoring a market near 6.6 billion dollars. Yet only 40 to 60 percent of patients reach a 50 percent reduction in monthly migraine days, the antibodies require injection, and the category remains symptomatic. Six decades on, the core gap holds. The field aborts attacks. It does not modify the disease. That is the problem BETR-001 is built for. A non-hallucinogenic, oral, repeat-dose neuroplastogen that engages the serotonin receptors with the deepest validated history in headache. And from a cardiac safety perspective, it is not a 5-HT2B agonist. The chronic-safety lessons of the earlier serotonergic agents are built into its development program. A fresh approach to chronic migraine steeped in validated MOA history. #Migraine #Neurology #CNS #DrugDevelopment

Two conditions. One enormous gap. Chronic migraine affects millions of people. Fifteen or more headache days a month, often more. The last decade brought real progress with CGRP therapies, and that progress mattered. But a large share of patients still don't respond well enough, can't tolerate what's available, or lose coverage the moment results fall short of a threshold someone else set. Most options are injected or infused. Too many people cycle through treatment after treatment and still lose days to pain. Chronic cluster headache is worse, and far lonelier. The pain ranks among the most severe a person can experience. People call it the suicide headache for a reason. Yet for the chronic form, the approved-treatment cupboard is nearly bare. This is the problem we get up for at @BetterLifeBio . There is real history behind our approach. Ergolines, the chemical family BETR-001 comes from, have been used in migraine and cluster headache for the better part of a century. Ergotamine and dihydroergotamine are still available today. Methysergide was once a mainstay for preventing both conditions. The class has a track record in exactly these diseases. What limited the older agents was tolerability and safety, and for methysergide in particular a rare fibrotic risk linked to activity at serotonin receptor 5-HT2B. In our preclinical work, BETR-001 does not activate that receptor. That is precisely the kind of need we are engineering around as we build a modern ergoline. BETR-001 is our investigational, non-hallucinogenic neuroplastogen. It is preclinical and advancing toward the clinic. What we hope for is simple. A different mechanism. An oral option. A real shot at reaching the people current therapies miss. That is worth the work.